Dawn M. Meyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dawn M. Meyer has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Brett C. Meyer
Department of Neurosciences, University of California, San Diego, California, USA
5 shared publications - Lovella Hailey
Neurosciences, University of California San Diego School of Medicine, San Diego, USA
3 shared publications Bruce Ovbiagele
2 shared publications- Rema Raman
University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA, 92093-0717, USA
2 shared publications - Thomas M. Hemmen
Dept of Neuroscience, Univ of California, San Diego, CA
2 shared publications Abhishek Lunagariya
Neurosciences, UCSD Stroke Cntr, La Jolla, CA
1 shared publication
Latest Publications
- Open Access
- 25 October 2019
- Published by Springer Nature in Cureus
- Vol. 11 (10) , e6000
PREMISE: Posterior Circulation Results Comparing Embolectomy to Medical Intervention in Stroke Emergencies
Intravenous (IV) tissue plasminogen activator (rt-PA) is a proven therapy for stroke in the acute treatment window. Recent published data has shown efficacy for embolectomy for acute ischemic strokes within up to six, 16 and 24 hours in the anterior circulation but there is no guideline for optimal therapy for patients with posterior circulation stroke, specifically basilar artery occlusion (BAO) outside the standard IV rt-PA treatment window. To evaluate differences in outcomes between maximal medical treatment versus thrombectomy in BAO. We retrospectively evaluated prospectively collected acute stroke code patients from our stroke registry from 7/2004 to 7/2016. Patients who received IV rt-PA were excluded. Patients with evidence of posterior circulation ischemia and a hyper dense artery sign on initial non-contrast CT were included as a surrogate for direct vessel data before 2014. Patients after 9/2014 were selected by evidence of BAO on vessel imaging. All patients were categorized either as endovascular therapy or standard medical treatment alone. Demographics, hospital discharge location and Modified Rankin Scale (mRS) at 90 days were compared. Two-sample t-test and Fisher’s exact test compared continuous and categorical variables across groups respectively. A total of 18 patients were included (three embolectomy and 15 medical therapy only). There were no significant differences in demographic data (age, gender, race, ethnicity, blood pressure, diabetes mellitus, hypertension, atrial fibrillation, tobacco use, alcohol use and initial NIHSS). Results for outcome and efficacies showed no statistical difference between medical management and endovascular intervention for functional outcome mRS (0-3) at 90 days (p = 0.2) and discharge location of home/inpatient rehabilitation vs other locations (p = 0.52). Our single-center review showed the expected transition from predominantly medically treated posterior circulation BAOs, to a mixed pattern including embolectomy. Although the sample size was small, this study also illustrates the lack of clear efficacy data for optimal treatment strategies, and the ongoing treatment challenges in posterior circulation stroke population in a population of patients outside the rt-PA window.
- 25 October 2019
- Published by Springer Nature in Cureus
- Vol. 11 (10) , e6000
Open AccessPREMISE: Posterior Circulation Results Comparing Embolectomy to Medical Intervention in Stroke Emergencies
Intravenous (IV) tissue plasminogen activator (rt-PA) is a proven therapy for stroke in the acute treatment window. Recent published data has shown efficacy for embolectomy for acute ischemic strokes within up to six, 16 and 24 hours in the anterior circulation but there is no guideline for optimal therapy for patients with posterior circulation stroke, specifically basilar artery occlusion (BAO) outside the standard IV rt-PA treatment window. To evaluate differences in outcomes between maximal medical treatment versus thrombectomy in BAO. We retrospectively evaluated prospectively collected acute stroke code patients from our stroke registry from 7/2004 to 7/2016. Patients who received IV rt-PA were excluded. Patients with evidence of posterior circulation ischemia and a hyper dense artery sign on initial non-contrast CT were included as a surrogate for direct vessel data before 2014. Patients after 9/2014 were selected by evidence of BAO on vessel imaging. All patients were categorized either as endovascular therapy or standard medical treatment alone. Demographics, hospital discharge location and Modified Rankin Scale (mRS) at 90 days were compared. Two-sample t-test and Fisher’s exact test compared continuous and categorical variables across groups respectively. A total of 18 patients were included (three embolectomy and 15 medical therapy only). There were no significant differences in demographic data (age, gender, race, ethnicity, blood pressure, diabetes mellitus, hypertension, atrial fibrillation, tobacco use, alcohol use and initial NIHSS). Results for outcome and efficacies showed no statistical difference between medical management and endovascular intervention for functional outcome mRS (0-3) at 90 days (p = 0.2) and discharge location of home/inpatient rehabilitation vs other locations (p = 0.52). Our single-center review showed the expected transition from predominantly medically treated posterior circulation BAOs, to a mixed pattern including embolectomy. Although the sample size was small, this study also illustrates the lack of clear efficacy data for optimal treatment strategies, and the ongoing treatment challenges in posterior circulation stroke population in a population of patients outside the rt-PA window.
- 1 January 2019
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 28 (1) , 163-166
Isolated Anisocoria as a Presenting Stroke Code Symptom is Unlikely to Result in Alteplase Administration
- 1 January 2019
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 28 (1) , 163-166
Isolated Anisocoria as a Presenting Stroke Code Symptom is Unlikely to Result in Alteplase Administration
- 8 October 2018
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 59, 355-357
Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment
- 8 October 2018
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 59, 355-357
Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract TMP23: Shades of White: Correlation of Hyperacute DWI Intensity With Last Known Well Time
Background: Identifying a last known well (LKW) time surrogate for acute stroke is vital to increase stroke treatment. Previous research have used an MRI DWI vs. FLAIR mismatch to estimate LKW time to within 6 hours. DWI signal intensity initially increases from onset of stroke, but mapping a reliable time course to the signal intensity has not been demonstrated. Methods: We retrospectively reviewed stroke code patients between 1/2016 and 6/2017 from the prospective, IRB approved UCSD Stroke Registry. Patients who had MRI brain from onset, with or without intervention, are included. All ischemic strokes were confirmed with ADC correlation and timing from onset to MRI was calculated. Raw DWI intensity was measured in grays (Gy) using IMPAX software and compared to contralateral side for control, for a relative DWI intensity (rDWI). LKW and MRI time were collected by chart review. Correlation was assessed using Pearson correlation coefficient between DWI intensity, rDWI, and time to MRI imaging. 1.5T, 3T, and combined modalities were examined. Results: 97 patients were included in this analysis. Overall, there is a good correlation (0.39, pConclusions: There is good correlation between DWI intensity and minutes from onset to MRI. This suggests a time-dependent DWI intensity response and supports the potential use of DWI intensity measurements to extrapolate a LKW time in unknown cases. Further studies in a larger dataset within the hyperacute period are being pursued to increase both experience and generalizability.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract TMP23: Shades of White: Correlation of Hyperacute DWI Intensity With Last Known Well Time
Background: Identifying a last known well (LKW) time surrogate for acute stroke is vital to increase stroke treatment. Previous research have used an MRI DWI vs. FLAIR mismatch to estimate LKW time to within 6 hours. DWI signal intensity initially increases from onset of stroke, but mapping a reliable time course to the signal intensity has not been demonstrated. Methods: We retrospectively reviewed stroke code patients between 1/2016 and 6/2017 from the prospective, IRB approved UCSD Stroke Registry. Patients who had MRI brain from onset, with or without intervention, are included. All ischemic strokes were confirmed with ADC correlation and timing from onset to MRI was calculated. Raw DWI intensity was measured in grays (Gy) using IMPAX software and compared to contralateral side for control, for a relative DWI intensity (rDWI). LKW and MRI time were collected by chart review. Correlation was assessed using Pearson correlation coefficient between DWI intensity, rDWI, and time to MRI imaging. 1.5T, 3T, and combined modalities were examined. Results: 97 patients were included in this analysis. Overall, there is a good correlation (0.39, pConclusions: There is good correlation between DWI intensity and minutes from onset to MRI. This suggests a time-dependent DWI intensity response and supports the potential use of DWI intensity measurements to extrapolate a LKW time in unknown cases. Further studies in a larger dataset within the hyperacute period are being pursued to increase both experience and generalizability.
- 1 September 2016
- Published by Elsevier in Neuroscience Letters
- Vol. 630, 254-258
Dose-finding study of phototherapy on stroke outcome in a rabbit model of ischemic stroke
- 1 September 2016
- Published by Elsevier in Neuroscience Letters
- Vol. 630, 254-258
Dose-finding study of phototherapy on stroke outcome in a rabbit model of ischemic stroke
- 1 January 2015
- Vol. 25 (1) , 19-23
Association of Hispanic ethnicity with acute ischemic stroke care processes and outcomes.
Few studies have examined the actual hospital arrival mode, emergency department (ED) care processes, and early outcomes in Hispanic vs non-Hispanic acute ischemic stroke (AIS) patients. We evaluated processes and prognosis by Hispanic ethnicity among AIS patients encountered in urban setting. We retrospectively reviewed prospectively-collected data on 1,117 AIS patients presenting within 12 hours of ictus to five hospitals in a tertiary-level stroke center network in San Diego, California. Variables of interest included pre-hospital factors, ED care processes, and favorable outcome (day-90 modified Rankin Scale [mRS] score of 0-1); all of which were adjusted for pre-specified covariates in a multivariable logistic regression model. There were 192 Hispanic AIS patients (17.2% of cohort) encountered from June 2004 to March 2011. Hispanic patients were significantly more likely to be younger, female, and diabetic. Hispanic patients arrived by ambulance (vs other arrival modes) less frequently (adjusted OR .56; 95% CI: .38-.81), trended toward a longer time of stroke onset to treatment decision (351.6 vs. 320.02 minutes, P=.07), and experienced a favorable day-90 outcome less often (adjusted OR .52, CI: .28-.96). However, for the day-90 outcome, there was no interaction between ambulance arrival and Hispanic ethnicity (P=.5614). Hispanic AIS patients in this study were less likely to arrive at the hospital by ambulance, and experienced half the odds of a favorable outcome compared to others. Strategies to boost ambulance utilization among Hispanic AIS patients and identify contributors to this worrisome outcome disparity are needed.
- 1 January 2015
- Vol. 25 (1) , 19-23
Association of Hispanic ethnicity with acute ischemic stroke care processes and outcomes.
Few studies have examined the actual hospital arrival mode, emergency department (ED) care processes, and early outcomes in Hispanic vs non-Hispanic acute ischemic stroke (AIS) patients. We evaluated processes and prognosis by Hispanic ethnicity among AIS patients encountered in urban setting. We retrospectively reviewed prospectively-collected data on 1,117 AIS patients presenting within 12 hours of ictus to five hospitals in a tertiary-level stroke center network in San Diego, California. Variables of interest included pre-hospital factors, ED care processes, and favorable outcome (day-90 modified Rankin Scale [mRS] score of 0-1); all of which were adjusted for pre-specified covariates in a multivariable logistic regression model. There were 192 Hispanic AIS patients (17.2% of cohort) encountered from June 2004 to March 2011. Hispanic patients were significantly more likely to be younger, female, and diabetic. Hispanic patients arrived by ambulance (vs other arrival modes) less frequently (adjusted OR .56; 95% CI: .38-.81), trended toward a longer time of stroke onset to treatment decision (351.6 vs. 320.02 minutes, P=.07), and experienced a favorable day-90 outcome less often (adjusted OR .52, CI: .28-.96). However, for the day-90 outcome, there was no interaction between ambulance arrival and Hispanic ethnicity (P=.5614). Hispanic AIS patients in this study were less likely to arrive at the hospital by ambulance, and experienced half the odds of a favorable outcome compared to others. Strategies to boost ambulance utilization among Hispanic AIS patients and identify contributors to this worrisome outcome disparity are needed.
- Open Access
- 1 January 2014
- Published by Springer Nature in Biology of Sex Differences
- Vol. 5 (1) , 9
rLOAD: does sex mediate the effect of acute antiplatelet loading on stroke outcome
Biologic sex can influence response to pharmacologic therapy. The purpose of this proof-of-concept study was to evaluate the medicating effects of estrogen in the efficacy of acute antiplatelet loading therapy on stroke outcome in the rabbit small clot embolic model.
- 1 January 2014
- Published by Springer Nature in Biology of Sex Differences
- Vol. 5 (1) , 9
Open AccessrLOAD: does sex mediate the effect of acute antiplatelet loading on stroke outcome
Biologic sex can influence response to pharmacologic therapy. The purpose of this proof-of-concept study was to evaluate the medicating effects of estrogen in the efficacy of acute antiplatelet loading therapy on stroke outcome in the rabbit small clot embolic model.
- 1 October 2013
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 22 (7) , 972-977
Diffusion-weighted Imaging–Fluid Attenuated Inversion Recovery Mismatch in Nocturnal Stroke Patients with Unknown Time of Onset
- 1 October 2013
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 22 (7) , 972-977
Diffusion-weighted Imaging–Fluid Attenuated Inversion Recovery Mismatch in Nocturnal Stroke Patients with Unknown Time of Onset
- Open Access
- 1 July 2011
- Published by SAGE Publications in Women's Health
- Vol. 7 (4) , 465-474
Sex Differences in Antiplatelet Response in Ischemic Stroke
Sex differences exist in the occurrence, treatment and outcome of ischemic stroke. Compared with men, women have more stroke events and are less likely to fully recover from a stroke. Given the rapidly aging population, stroke incidence and mortality among women are projected to substantially rise by 2050. This has important public health consequences. Mitigating the burden of stroke among women will require a fundamental understanding of sex differences and sex-specific issues including cerebrovascular disease pathophysiology, treatment and outcome. An aspect of stroke treatment receiving increasing but insufficient attention involves possible interactions between estrogen levels, antiplatelet drugs and stroke outcome. Emerging evidence suggests that antiplatelet therapy may provide primary stroke protection but not primary myocardial infarction prevention in women, while the opposite may be true among men. Understanding sex-specific issues related to women who experience stroke is critical to clinicians who treat women with antiplatelet medications as part of a secondary stroke prevention regimen; however, the ideal antiplatelet medication, and dose, in women requires further research. In this article we present a conceptual framework for sex differences in antiplatelet treatment response in ischemic stroke, thrombus formation and the mediating role of estrogen, sex differences in antiplatelet treatment response in clinical trials, and sex differences in antiplatelet treatment use in ischemic stroke.
- 1 July 2011
- Published by SAGE Publications in Women's Health
- Vol. 7 (4) , 465-474
Open AccessSex Differences in Antiplatelet Response in Ischemic Stroke
Sex differences exist in the occurrence, treatment and outcome of ischemic stroke. Compared with men, women have more stroke events and are less likely to fully recover from a stroke. Given the rapidly aging population, stroke incidence and mortality among women are projected to substantially rise by 2050. This has important public health consequences. Mitigating the burden of stroke among women will require a fundamental understanding of sex differences and sex-specific issues including cerebrovascular disease pathophysiology, treatment and outcome. An aspect of stroke treatment receiving increasing but insufficient attention involves possible interactions between estrogen levels, antiplatelet drugs and stroke outcome. Emerging evidence suggests that antiplatelet therapy may provide primary stroke protection but not primary myocardial infarction prevention in women, while the opposite may be true among men. Understanding sex-specific issues related to women who experience stroke is critical to clinicians who treat women with antiplatelet medications as part of a secondary stroke prevention regimen; however, the ideal antiplatelet medication, and dose, in women requires further research. In this article we present a conceptual framework for sex differences in antiplatelet treatment response in ischemic stroke, thrombus formation and the mediating role of estrogen, sex differences in antiplatelet treatment response in clinical trials, and sex differences in antiplatelet treatment use in ischemic stroke.